Zelluna ASA
OSE:ZLNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zelluna ASA
OSE:ZLNA
|
NO |
|
C
|
Carasso Real Estate Ltd
TASE:CRSR
|
IL |
|
I
|
Immsi SpA
SWB:IMY
|
IT |
Zelluna ASA
Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo and currently employs 26 full-time employees. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.
Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo and currently employs 26 full-time employees. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.
